Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator
•Edaravone may be a good partner for combination therapy with tPA to enhance recanalization.•The radical scavengers could improve coagulation condition in cerebral infarction.•Edaravone could reduce the risk of hemorrhagic transformation and neurotoxic effects induced by rtPA.•Edaravone improved out...
Gespeichert in:
| Veröffentlicht in: | Clinical neurology and neurosurgery 2018-04, Vol.167, p.157-161 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 161 |
|---|---|
| container_issue | |
| container_start_page | 157 |
| container_title | Clinical neurology and neurosurgery |
| container_volume | 167 |
| creator | Lee, Xian-Ru Xiang, Gui-Ling |
| description | •Edaravone may be a good partner for combination therapy with tPA to enhance recanalization.•The radical scavengers could improve coagulation condition in cerebral infarction.•Edaravone could reduce the risk of hemorrhagic transformation and neurotoxic effects induced by rtPA.•Edaravone improved outcomes of acute cerebral infarction patients treated with rt-PA.
Edaravone, a free radical scavenger, alleviates blood-brain barrier disruption in conjunction with suppression of the inflammatory reaction in acute cerebral infarction. Thrombolysis with recombinant tissue plasminogen activator (rtPA) is an established therapy for acute cerebral infarction patients. The purpose of this study was to assess the effects of edaravone on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.
We conducted a retrospective cohort study using the database of Ningbo First Hospital. We identified patients who were admitted with a primary diagnosis of acute cerebral infarction and treated with intravenous rtPA(iv-rtPA) within 3 h of symptom onset from March 1st in 2014 to October 31st in 2016.Thenceforth,the patients were divided into 2 groups by treatment with(edaravone group) or without edaravone(non-edaravone group). Glasgow Coma Scale (GCS) scores and mRS score at admission were used. Clinical background, risk factors for acute cerebral infarction hemorrhagic transformation, 7-day mortality, recanalization rate, bleeding complications and blood rheology indexes were collected. We also collected the following factors: National Institutes of Health Stroke Scale scores, barthel index.
136 patients treated without edaravone during hospitalization were selected in non-edaravone group while edaravone group included 132 patients treated with edaravone during hospitalization. The patient baseline distributions were well balanced between non-edaravone group and edaravone group. The rate of hemorrhagic transformation in non-edaravone group was higher than that in edaravone group (P ＜ 0.05). The NIHSS scores 7 days and 14 days after symptom onset were higher in non-edaravone group than in edaravone group (both P ＜ 0.05). Edaravone group showed a higher recanalization rate and a lower bleeding complications rate at discharge than the non-edaravone group (both P ＜ 0.05). The differences of all the blood rheology indexes between the two groups were statistically significant (all P ＜ 0.05).
Edaravone may improve outcomes of acute cerebral infarc |
| doi_str_mv | 10.1016/j.clineuro.2018.02.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2010374623</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303846718300775</els_id><sourcerecordid>2010374623</sourcerecordid><originalsourceid>FETCH-LOGICAL-c396t-4f703544b9b6dd5ea0b030d6a8d0464c26d5f9928dc4381471f7d0b62606ad9e3</originalsourceid><addsrcrecordid>eNqFkUFv1DAQhSMEokvhL1SWuHBoFjt2nOQGqgpFqsQFzpZjj1uvEnsZO1vtD-P_4bAth16QRprL994bvamqC0a3jDL5cbc1kw-wYNw2lPVb2pSRL6oN67umloPsX1YbyimveyG7s-pNSjtKKeeyf12dNUNLGRXtpvp97RyYnEh0BKxGfYgBLkm-B-IQgKC23uiJJKMPEO4AL0kMJC7ZxBkS8YFos2QgBhBGLKAPTqPJvlB7nT2E4p0RdAZLHny-J8uUUdegcTqWGIzzGKdj8n8vQCi2ow86ZJJ9SguQ_aTT7EO8gzUq-4POEd9Wr5yeErx73OfVzy_XP65u6tvvX79dfb6tDR9kroXrKG-FGIdRWtuCpmOpxErdWyqkMI20rRuGprdG8J6JjrnO0lE2kkptB-Dn1YeT7x7jrwVSVrNPBqZJB4hLUqV6yjshG17Q98_QXVwwlOtWqmMrJAslT5TBmBKCU3v0s8ajYlStj1U79fTYVdcr2pRZhReP9ss4g_0ne_pkAT6dACh9HDygSqa0b8D60mpWNvr_ZfwB2wq8HQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2017146236</pqid></control><display><type>article</type><title>Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Lee, Xian-Ru ; Xiang, Gui-Ling</creator><creatorcontrib>Lee, Xian-Ru ; Xiang, Gui-Ling</creatorcontrib><description>•Edaravone may be a good partner for combination therapy with tPA to enhance recanalization.•The radical scavengers could improve coagulation condition in cerebral infarction.•Edaravone could reduce the risk of hemorrhagic transformation and neurotoxic effects induced by rtPA.•Edaravone improved outcomes of acute cerebral infarction patients treated with rt-PA.
Edaravone, a free radical scavenger, alleviates blood-brain barrier disruption in conjunction with suppression of the inflammatory reaction in acute cerebral infarction. Thrombolysis with recombinant tissue plasminogen activator (rtPA) is an established therapy for acute cerebral infarction patients. The purpose of this study was to assess the effects of edaravone on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.
We conducted a retrospective cohort study using the database of Ningbo First Hospital. We identified patients who were admitted with a primary diagnosis of acute cerebral infarction and treated with intravenous rtPA(iv-rtPA) within 3 h of symptom onset from March 1st in 2014 to October 31st in 2016.Thenceforth,the patients were divided into 2 groups by treatment with(edaravone group) or without edaravone(non-edaravone group). Glasgow Coma Scale (GCS) scores and mRS score at admission were used. Clinical background, risk factors for acute cerebral infarction hemorrhagic transformation, 7-day mortality, recanalization rate, bleeding complications and blood rheology indexes were collected. We also collected the following factors: National Institutes of Health Stroke Scale scores, barthel index.
136 patients treated without edaravone during hospitalization were selected in non-edaravone group while edaravone group included 132 patients treated with edaravone during hospitalization. The patient baseline distributions were well balanced between non-edaravone group and edaravone group. The rate of hemorrhagic transformation in non-edaravone group was higher than that in edaravone group (P ＜ 0.05). The NIHSS scores 7 days and 14 days after symptom onset were higher in non-edaravone group than in edaravone group (both P ＜ 0.05). Edaravone group showed a higher recanalization rate and a lower bleeding complications rate at discharge than the non-edaravone group (both P ＜ 0.05). The differences of all the blood rheology indexes between the two groups were statistically significant (all P ＜ 0.05).
Edaravone may improve outcomes of acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.</description><identifier>ISSN: 0303-8467</identifier><identifier>EISSN: 1872-6968</identifier><identifier>DOI: 10.1016/j.clineuro.2018.02.026</identifier><identifier>PMID: 29501045</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Blood pressure ; Brain Ischemia - drug therapy ; Brain research ; Cardiovascular disease ; Cerebral infarction ; Coma ; Drugs ; Edaravone - pharmacology ; Edaravone-acute cerebral infarction-recombinant tissue plasminogen activator- thrombolysis ; Female ; Fibrinolytic Agents - therapeutic use ; Free Radical Scavengers - therapeutic use ; Free radicals ; Humans ; Ischemia ; Liver diseases ; Male ; Mortality ; R&D ; Research & development ; Retrospective Studies ; Risk Factors ; Stroke ; Studies ; t-Plasminogen activator ; Thrombolysis ; Tissue Plasminogen Activator - pharmacology ; Treatment Outcome</subject><ispartof>Clinical neurology and neurosurgery, 2018-04, Vol.167, p.157-161</ispartof><rights>2018 Elsevier B.V.</rights><rights>Copyright © 2018 Elsevier B.V. All rights reserved.</rights><rights>Copyright Elsevier Limited 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c396t-4f703544b9b6dd5ea0b030d6a8d0464c26d5f9928dc4381471f7d0b62606ad9e3</citedby><cites>FETCH-LOGICAL-c396t-4f703544b9b6dd5ea0b030d6a8d0464c26d5f9928dc4381471f7d0b62606ad9e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2017146236?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29501045$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Xian-Ru</creatorcontrib><creatorcontrib>Xiang, Gui-Ling</creatorcontrib><title>Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator</title><title>Clinical neurology and neurosurgery</title><addtitle>Clin Neurol Neurosurg</addtitle><description>•Edaravone may be a good partner for combination therapy with tPA to enhance recanalization.•The radical scavengers could improve coagulation condition in cerebral infarction.•Edaravone could reduce the risk of hemorrhagic transformation and neurotoxic effects induced by rtPA.•Edaravone improved outcomes of acute cerebral infarction patients treated with rt-PA.
Edaravone, a free radical scavenger, alleviates blood-brain barrier disruption in conjunction with suppression of the inflammatory reaction in acute cerebral infarction. Thrombolysis with recombinant tissue plasminogen activator (rtPA) is an established therapy for acute cerebral infarction patients. The purpose of this study was to assess the effects of edaravone on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.
We conducted a retrospective cohort study using the database of Ningbo First Hospital. We identified patients who were admitted with a primary diagnosis of acute cerebral infarction and treated with intravenous rtPA(iv-rtPA) within 3 h of symptom onset from March 1st in 2014 to October 31st in 2016.Thenceforth,the patients were divided into 2 groups by treatment with(edaravone group) or without edaravone(non-edaravone group). Glasgow Coma Scale (GCS) scores and mRS score at admission were used. Clinical background, risk factors for acute cerebral infarction hemorrhagic transformation, 7-day mortality, recanalization rate, bleeding complications and blood rheology indexes were collected. We also collected the following factors: National Institutes of Health Stroke Scale scores, barthel index.
136 patients treated without edaravone during hospitalization were selected in non-edaravone group while edaravone group included 132 patients treated with edaravone during hospitalization. The patient baseline distributions were well balanced between non-edaravone group and edaravone group. The rate of hemorrhagic transformation in non-edaravone group was higher than that in edaravone group (P ＜ 0.05). The NIHSS scores 7 days and 14 days after symptom onset were higher in non-edaravone group than in edaravone group (both P ＜ 0.05). Edaravone group showed a higher recanalization rate and a lower bleeding complications rate at discharge than the non-edaravone group (both P ＜ 0.05). The differences of all the blood rheology indexes between the two groups were statistically significant (all P ＜ 0.05).
Edaravone may improve outcomes of acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.</description><subject>Blood pressure</subject><subject>Brain Ischemia - drug therapy</subject><subject>Brain research</subject><subject>Cardiovascular disease</subject><subject>Cerebral infarction</subject><subject>Coma</subject><subject>Drugs</subject><subject>Edaravone - pharmacology</subject><subject>Edaravone-acute cerebral infarction-recombinant tissue plasminogen activator- thrombolysis</subject><subject>Female</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Free Radical Scavengers - therapeutic use</subject><subject>Free radicals</subject><subject>Humans</subject><subject>Ischemia</subject><subject>Liver diseases</subject><subject>Male</subject><subject>Mortality</subject><subject>R&D</subject><subject>Research & development</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stroke</subject><subject>Studies</subject><subject>t-Plasminogen activator</subject><subject>Thrombolysis</subject><subject>Tissue Plasminogen Activator - pharmacology</subject><subject>Treatment Outcome</subject><issn>0303-8467</issn><issn>1872-6968</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkUFv1DAQhSMEokvhL1SWuHBoFjt2nOQGqgpFqsQFzpZjj1uvEnsZO1vtD-P_4bAth16QRprL994bvamqC0a3jDL5cbc1kw-wYNw2lPVb2pSRL6oN67umloPsX1YbyimveyG7s-pNSjtKKeeyf12dNUNLGRXtpvp97RyYnEh0BKxGfYgBLkm-B-IQgKC23uiJJKMPEO4AL0kMJC7ZxBkS8YFos2QgBhBGLKAPTqPJvlB7nT2E4p0RdAZLHny-J8uUUdegcTqWGIzzGKdj8n8vQCi2ow86ZJJ9SguQ_aTT7EO8gzUq-4POEd9Wr5yeErx73OfVzy_XP65u6tvvX79dfb6tDR9kroXrKG-FGIdRWtuCpmOpxErdWyqkMI20rRuGprdG8J6JjrnO0lE2kkptB-Dn1YeT7x7jrwVSVrNPBqZJB4hLUqV6yjshG17Q98_QXVwwlOtWqmMrJAslT5TBmBKCU3v0s8ajYlStj1U79fTYVdcr2pRZhReP9ss4g_0ne_pkAT6dACh9HDygSqa0b8D60mpWNvr_ZfwB2wq8HQ</recordid><startdate>20180401</startdate><enddate>20180401</enddate><creator>Lee, Xian-Ru</creator><creator>Xiang, Gui-Ling</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20180401</creationdate><title>Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator</title><author>Lee, Xian-Ru ; Xiang, Gui-Ling</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c396t-4f703544b9b6dd5ea0b030d6a8d0464c26d5f9928dc4381471f7d0b62606ad9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Blood pressure</topic><topic>Brain Ischemia - drug therapy</topic><topic>Brain research</topic><topic>Cardiovascular disease</topic><topic>Cerebral infarction</topic><topic>Coma</topic><topic>Drugs</topic><topic>Edaravone - pharmacology</topic><topic>Edaravone-acute cerebral infarction-recombinant tissue plasminogen activator- thrombolysis</topic><topic>Female</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Free Radical Scavengers - therapeutic use</topic><topic>Free radicals</topic><topic>Humans</topic><topic>Ischemia</topic><topic>Liver diseases</topic><topic>Male</topic><topic>Mortality</topic><topic>R&D</topic><topic>Research & development</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stroke</topic><topic>Studies</topic><topic>t-Plasminogen activator</topic><topic>Thrombolysis</topic><topic>Tissue Plasminogen Activator - pharmacology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Xian-Ru</creatorcontrib><creatorcontrib>Xiang, Gui-Ling</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical neurology and neurosurgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Xian-Ru</au><au>Xiang, Gui-Ling</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator</atitle><jtitle>Clinical neurology and neurosurgery</jtitle><addtitle>Clin Neurol Neurosurg</addtitle><date>2018-04-01</date><risdate>2018</risdate><volume>167</volume><spage>157</spage><epage>161</epage><pages>157-161</pages><issn>0303-8467</issn><eissn>1872-6968</eissn><abstract>•Edaravone may be a good partner for combination therapy with tPA to enhance recanalization.•The radical scavengers could improve coagulation condition in cerebral infarction.•Edaravone could reduce the risk of hemorrhagic transformation and neurotoxic effects induced by rtPA.•Edaravone improved outcomes of acute cerebral infarction patients treated with rt-PA.
Edaravone, a free radical scavenger, alleviates blood-brain barrier disruption in conjunction with suppression of the inflammatory reaction in acute cerebral infarction. Thrombolysis with recombinant tissue plasminogen activator (rtPA) is an established therapy for acute cerebral infarction patients. The purpose of this study was to assess the effects of edaravone on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.
We conducted a retrospective cohort study using the database of Ningbo First Hospital. We identified patients who were admitted with a primary diagnosis of acute cerebral infarction and treated with intravenous rtPA(iv-rtPA) within 3 h of symptom onset from March 1st in 2014 to October 31st in 2016.Thenceforth,the patients were divided into 2 groups by treatment with(edaravone group) or without edaravone(non-edaravone group). Glasgow Coma Scale (GCS) scores and mRS score at admission were used. Clinical background, risk factors for acute cerebral infarction hemorrhagic transformation, 7-day mortality, recanalization rate, bleeding complications and blood rheology indexes were collected. We also collected the following factors: National Institutes of Health Stroke Scale scores, barthel index.
136 patients treated without edaravone during hospitalization were selected in non-edaravone group while edaravone group included 132 patients treated with edaravone during hospitalization. The patient baseline distributions were well balanced between non-edaravone group and edaravone group. The rate of hemorrhagic transformation in non-edaravone group was higher than that in edaravone group (P ＜ 0.05). The NIHSS scores 7 days and 14 days after symptom onset were higher in non-edaravone group than in edaravone group (both P ＜ 0.05). Edaravone group showed a higher recanalization rate and a lower bleeding complications rate at discharge than the non-edaravone group (both P ＜ 0.05). The differences of all the blood rheology indexes between the two groups were statistically significant (all P ＜ 0.05).
Edaravone may improve outcomes of acute cerebral infarction patients treated with ultra-early thrombolysis of iv-rt-PA.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>29501045</pmid><doi>10.1016/j.clineuro.2018.02.026</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0303-8467 |
| ispartof | Clinical neurology and neurosurgery, 2018-04, Vol.167, p.157-161 |
| issn | 0303-8467 1872-6968 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2010374623 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | Blood pressure Brain Ischemia - drug therapy Brain research Cardiovascular disease Cerebral infarction Coma Drugs Edaravone - pharmacology Edaravone-acute cerebral infarction-recombinant tissue plasminogen activator- thrombolysis Female Fibrinolytic Agents - therapeutic use Free Radical Scavengers - therapeutic use Free radicals Humans Ischemia Liver diseases Male Mortality R&D Research & development Retrospective Studies Risk Factors Stroke Studies t-Plasminogen activator Thrombolysis Tissue Plasminogen Activator - pharmacology Treatment Outcome |
| title | Effects of edaravone, the free radical scavenger, on outcomes in acute cerebral infarction patients treated with ultra-early thrombolysis of recombinant tissue plasminogen activator |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T03%3A36%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20edaravone,%20the%20free%20radical%20scavenger,%20on%20outcomes%20in%20acute%20cerebral%20infarction%20patients%20treated%20with%20ultra-early%20thrombolysis%20of%20recombinant%20tissue%20plasminogen%20activator&rft.jtitle=Clinical%20neurology%20and%20neurosurgery&rft.au=Lee,%20Xian-Ru&rft.date=2018-04-01&rft.volume=167&rft.spage=157&rft.epage=161&rft.pages=157-161&rft.issn=0303-8467&rft.eissn=1872-6968&rft_id=info:doi/10.1016/j.clineuro.2018.02.026&rft_dat=%3Cproquest_cross%3E2010374623%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2017146236&rft_id=info:pmid/29501045&rft_els_id=S0303846718300775&rfr_iscdi=true |